Bicara Therapeutics (NASDAQ:BCAX) Trading Down 4.1% – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX) dropped 4.1% on Thursday . The company traded as low as $12.35 and last traded at $12.39. Approximately 237,476 shares were traded during trading, a decline of 38% from the average daily volume of 381,444 shares. The stock had previously closed at $12.92.

Wall Street Analysts Forecast Growth

BCAX has been the subject of a number of research analyst reports. Morgan Stanley assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price for the company. Cantor Fitzgerald initiated coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating for the company. TD Cowen started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Finally, HC Wainwright started coverage on shares of Bicara Therapeutics in a research note on Friday, December 6th. They issued a “buy” rating and a $42.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics has an average rating of “Buy” and a consensus price target of $43.00.

Bicara Therapeutics Stock Performance

The firm has a 50 day simple moving average of $18.11.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Equities research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Several large investors have recently modified their holdings of BCAX. SG Americas Securities LLC bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $147,000. Cinctive Capital Management LP bought a new stake in Bicara Therapeutics in the 3rd quarter valued at $229,000. Barclays PLC acquired a new stake in Bicara Therapeutics in the 3rd quarter worth $255,000. Jane Street Group LLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $309,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in shares of Bicara Therapeutics during the third quarter valued at about $358,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.